Healthcare / BiotechnologyNasdaqGM
$6.91
-0.16 (-2.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-44.7M · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$268M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-47.0%
↓Gross Margin
N/A
•Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-509.6%
FCF / Net income
0.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $25.4M · net income $-143.8M · FCF $-129.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $25.4M | $25.4M | $210.8M | $129.0M | — | — | — |
| Net Income | $-143.8M | $-143.8M | $65.6M | $-6.7M | $-94.6M | $-51.2M | $-26.5M |
| EBITDA | $-153.8M | $-153.8M | $50.8M | $-321000.00 | $-95.4M | — | — |
| EPS | -3.47 | -3.47 | 1.68 | -0.20 | -3.02 | -8.16 | -24.00 |
| Operating Margin | -621.1% | -621.1% | 22.3% | -2.5% | — | — | — |
| Net Margin | -565.5% | -565.5% | 31.1% | -5.2% | — | — | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.17 | 0.17 | 0.14 | 0.28 | 0.12 | — | — |
| Current Ratio | 13.90 | 13.90 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-129.6M | $-129.6M | $-44.7M | $134.2M | $-96.7M | $-55.4M | $-27.9M |
| Returns | |||||||
| ROE | -47.0% | -47.0% | 15.3% | -2.8% | -44.5% | -17.1% | 63.9% |
| Valuation | |||||||
| P/E | — | — | 10.90 | — | — | — | — |
| EV/EBITDA | — | — | 13.24 | — | — | — | — |
| P/B | 0.93 | 0.93 | 1.67 | 2.08 | 2.10 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | -87.9% | -87.9% | 63.4% | — | — | — | — |
| EPS Growth | -306.5% | -306.5% | 940.0% | 93.4% | — | 66.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.1%
Start / end P/E
n/dx → n/dx
EPS bridge
1.68 → -3.47
Residual
-9.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.